Surfactant for meconium aspiration syndrome in full term infants

Protein content and biophysical properties of tracheal aspirates form neonates with respiratory failure1

“…Elevated E-a 1 -PI levels in group 2 support the concept of increased alveolar-capillary membrane permeability caused at least in part by inflammatory mechanisms. We speculate that exogenous surfactant administration will gain increasing importance in this group as already shown in clinical trials [14,20,25,39].…”

Protein content and biophysical properties of tracheal aspirates form neonates with respiratory failure1

“…Elevated E-a 1 -PI levels in group 2 support the concept of increased alveolar-capillary membrane permeability caused at least in part by inflammatory mechanisms. We speculate that exogenous surfactant administration will gain increasing importance in this group as already shown in clinical trials [14,20,25,39].…”

Recent Clinical Trials of Surfactant Treatment for Neonates

“…A systematic review of surfactant for MAS [4] which was conducted before the Chinese trial [23] had been published concluded that, whilst treatment may reduce the severity of respiratory illness and the need for extracorporeal membrane oxygenation (ECMO), further trials were needed. 2 Two trials were in children rather than neonates and 1 study involved an animal model.…”

Treatment of severe meconium aspiration syndrome with porcine surfactant: A multicentre, randomized, controlled trial

“…Curosurf treatment (3.2% vs 10%). Taken together, the studies suggest that, in babies with severe MAS and clinical evidence of intractable respiratory failure, early intervention with exogenous surfactant could improve oxygenation and prevent the need for ECMO [13]. Further larger and systematic studies of surfactant treatment for MAS should be performed comparing single and multiple doses, and high and low dose (e.g.…”

Protein content and biophysical properties of tracheal aspirates form neonates with respiratory failure1

“…Elevated E-a 1 -PI levels in group 2 support the concept of increased alveolar-capillary membrane permeability caused at least in part by inflammatory mechanisms. We speculate that exogenous surfactant administration will gain increasing importance in this group as already shown in clinical trials [14,20,25,39].…”

Recent Clinical Trials of Surfactant Treatment for Neonates

“…A systematic review of surfactant for MAS [4] which was conducted before the Chinese trial [23] had been published concluded that, whilst treatment may reduce the severity of respiratory illness and the need for extracorporeal membrane oxygenation (ECMO), further trials were needed. 2 Two trials were in children rather than neonates and 1 study involved an animal model.…”

Treatment of severe meconium aspiration syndrome with porcine surfactant: A multicentre, randomized, controlled trial

“…Curosurf treatment (3.2% vs 10%). Taken together, the studies suggest that, in babies with severe MAS and clinical evidence of intractable respiratory failure, early intervention with exogenous surfactant could improve oxygenation and prevent the need for ECMO [13]. Further larger and systematic studies of surfactant treatment for MAS should be performed comparing single and multiple doses, and high and low dose (e.g.…”

Protein content and biophysical properties of tracheal aspirates form neonates with respiratory failure1

“…Elevated E-a 1 -PI levels in group 2 support the concept of increased alveolar-capillary membrane permeability caused at least in part by inflammatory mechanisms. We speculate that exogenous surfactant administration will gain increasing importance in this group as already shown in clinical trials [14,20,25,39].…”

Recent Clinical Trials of Surfactant Treatment for Neonates

“…A systematic review of surfactant for MAS [4] which was conducted before the Chinese trial [23] had been published concluded that, whilst treatment may reduce the severity of respiratory illness and the need for extracorporeal membrane oxygenation (ECMO), further trials were needed. 2 Two trials were in children rather than neonates and 1 study involved an animal model.…”

Treatment of severe meconium aspiration syndrome with porcine surfactant: A multicentre, randomized, controlled trial

“…Curosurf treatment (3.2% vs 10%). Taken together, the studies suggest that, in babies with severe MAS and clinical evidence of intractable respiratory failure, early intervention with exogenous surfactant could improve oxygenation and prevent the need for ECMO [13]. Further larger and systematic studies of surfactant treatment for MAS should be performed comparing single and multiple doses, and high and low dose (e.g.…”